Eli Lilly and Company has entered into a definitive agreement to acquire privately held biotechnology company Calytrix Bio, Inc. in a transaction valued at up to $1.5 billion in cash. The deal adds a preclinical antibody programme targeting mutant calreticulin (mCALR) to Lilly’s pipeline for myeloproliferative neoplasms (MPNs), including essential thrombocythemia and myelofibrosis.
Under the agreement, Calytrix shareholders may receive an upfront payment followed by additional payments linked to the achievement of clinical and regulatory milestones. The upfront amount and expected closing date have not been disclosed.
A preclinical antibody targeting mutant calreticulin
Calytrix’s lead programme is a biparatopic antibody designed to target mutant calreticulin (mCALR), a protein associated with certain myeloproliferative neoplasms.
The investigational molecule is being developed for patients with mCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF). Its design aims to recognise both major mutation types, Type 1 and Type 2. According to Citi analysts cited by Fierce Biotech, these mutations together are found in approximately one-quarter of patients with ET and primary MF.
The therapeutic approach focuses on mutant CALR as a disease-associated cell-surface target. According to the company, the antibody is designed to selectively eliminate cells carrying the mutant protein while sparing healthy tissues and preserving normal blood-cell production.
Unlike existing treatment approaches that primarily address symptoms and disease complications, the programme is intended to target the underlying disease-driving cell population.
However, the candidate remains at the preclinical stage and has not yet entered human clinical trials. Its proposed mechanism, safety profile and potential disease-modifying effects therefore remain to be established through further development.
Calytrix CEO Brad Prosek said the company had been established with the aim of developing therapies capable of altering the course of mCALR-driven ET and MF. He added that the agreement would enable Lilly to advance the programme through clinical development and investigate its potential across the disease spectrum.
Complementing Lilly’s acquisition of Ajax Therapeutics
The Calytrix agreement follows Lilly’s April 2026 announcement that it would acquire Ajax Therapeutics in a transaction valued at up to $2.3 billion.
The Ajax acquisition provided Lilly with AJ1-11095, an investigational once-daily oral Type II JAK2 inhibitor being evaluated in a Phase 1 clinical trial for patients with myelofibrosis previously treated with a Type I JAK2 inhibitor.
The two programmes address different aspects of MPN biology. AJ1-11095 targets JAK2 signalling, a pathway involved in disease progression, whereas Calytrix’s antibody is designed to target the mutant CALR-expressing disease-driving cell population.
This creates a potential strategic opportunity to explore complementary treatment approaches. According to analysts at Citi cited by Fierce Biotech, an mCALR-targeting antibody could be investigated as a monotherapy or in combination with a JAK2 inhibitor.
However, the feasibility of combination treatment, appropriate dosing strategies and the potential to reverse established bone marrow fibrosis have not been demonstrated.
The analysts also highlighted the particularly high safety requirements for a therapy intended for essential thrombocythemia, which can follow a relatively indolent clinical course.
Calytrix Bio’s origins and investors
Calytrix Bio was founded in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences investment arm of J.P. Morgan Asset Management.
The company launched with a Series A financing round co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners. A subsequent Series B financing was led by Avoro Ventures.
Calytrix is headquartered in Wellesley Hills, Massachusetts.
For further background on the company’s development and manufacturing history, see our overview of Eli Lilly’s evolution from a pharmacy into a GMP-compliant pharmaceutical manufacturer.
Centerview Partners LLC is acting as the company’s exclusive financial adviser, while Goodwin Procter LLP is providing legal counsel. Eli Lilly is being advised by Paul, Weiss, Rifkind, Wharton & Garrison LLP.


